



P R E D I C T M E D I X

Disruptive AI Powered Technologies for Healthcare

PREDICTMEDIX.COM

PMED : CSE PMEDF : OTCQB



Disclaimer

Complete disclaimer in investment memorandum

This document provides a summary description of PREDICTMEDIX Inc. ("PREDICTMEDIX"), its subsidiary companies and its business and does not purport to be complete. Prospective investors are encouraged to obtain independent legal advice concerning any investment in securities of PREDICTMEDIX and should not base their decision on whether to invest in PREDICTMEDIX upon the material provided herein. There are no representations or warranties made herein by PREDICTMEDIX or the agents of the proposed offering of units of PREDICTMEDIX (the "Agents") and investors will only be able to rely on the representations and warranties contained in the subscription agreement to be entered into at the time of sale of the securities. This document is strictly confidential and has been prepared solely for use in connection with the offering of the securities described herein.

Neither this document nor any of its contents are to be distributed to third parties without the prior written consent of PREDICTMEDIX and its Agents. There are certain risks inherent in an investment in the securities of PREDICTMEDIX which prospective investors should carefully consider before investing in the securities of PREDICTMEDIX. This document constitutes an offering of the securities described herein only in those jurisdictions and to those persons where and to whom they may be lawfully offered for sale, and only by persons permitted to sell these securities. This document is not, and under no circumstances is it to be construed as, an advertisement or a public offering of these securities. This document is personal to each offeree and does not constitute an offer to any other person or to the public generally to subscribe for or otherwise acquire any of the securities referred to herein. No securities regulatory authority or similar authority has reviewed or in any way passed upon the document or the merits of these securities and any representation to the contrary is an offence.

This document has been prepared for information purposes only in order to assist prospective investors in evaluating an investment in PREDICTMEDIX. By accepting delivery of this document or any other information in connection with an investment in PREDICTMEDIX, the investor agrees: (1) to keep strictly confidential the contents of this presentation and such other information and not to disclose such document, the contents thereof or any such information to any third party or otherwise use the information for any purpose other than evaluation by such prospective investor/offeree of an investment in the securities; (2) not to copy all or any portion of this document, or any such other information; and (3) to return this document and all such other documents and information to PREDICTMEDIX or the Agents upon the request of PREDICTMEDIX or the Agents.

No representation, warranty or undertaking, expressed or implied, is made and no responsibility or liability is accepted by the Agents as to the accuracy or completeness of the information contained herein or any other information, representation, warranty or undertaking, express or implied, made by PREDICTMEDIX in connection with the offering of securities described herein.

Forward-looking information


This investor document contains statements that, to the extent that they are not historical fact, may constitute "forward-looking statements" within the meaning of applicable securities legislation. Any statements regarding future plans, objectives or economic performance of PREDICTMEDIX, or the assumption underlying any of the foregoing, constitute forward-looking information. This investor document uses words such as "may", "would", "could", "will", "likely", "except", "anticipate", "believe", "intend", "plan", "forecast", "project", "estimate", "outlook", and other similar expressions to identify forward-looking statements. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this investor document, and, accordingly, investors should not place undue reliance on any such forward-looking statements. Forward-looking information involves significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements and accordingly, should not be read as guarantees of future performance or results. Any forward-looking statements speak only as of the date on which such statement is made and each of PREDICTMEDIX and the Agents disclaims any intention or obligation to update or revise any forward-looking information, where as a result of new information, future events or otherwise, unless required by applicable law. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of each such factor on PREDICTMEDIX's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

The Company reserves the right to request the return of the Information at any time.







COVID-19 & Infectious Diseases



Cannabis & Alcohol Impairment



Mental Illnesses



Virtual Care



The Opportunity

Bring advanced AI technology to power the world's HealthTech wave

\$13.9B USD

Drug Screening Market
Forecast for 2027

\$1.4B USD

Cannabis Screening
Market Forecast for 2021

\$5.0B USD

Respiratory Disease
Screening Market in 2016

\$13.0B USD

AI in Healthcare Market
Size for 2025

\$2.1B USD

Mental Healthcare
Software Market in 2019

\$250.0B USD

Virtual Health Market
Size for 2021

It all adds up
to explain why
PredictMedix is
developing its
**AI HealthTech
solutions!**



Who We Are

PREDICTMEDIX is an AI (Artificial Intelligence) company developing disruptive technologies for health and safety in workplaces and healthcare.

Rapid Mass Screening

Using multispectral cameras and sensors to capture data patterns that are instantly analyzed by our AI models

Covid-19 &
Infectious Disease
Symptom Screening

Cannabis &
Alcohol Impairment
Screening

Mental
Illness
Diagnostics

Remote Patient Care

A remote monitoring telehealth platform integrating wearables and Bluetooth devices that bring data together with compassionate care tools for specific applications

Long Term Care
& Retirement
Residence Care

Clinical Study
Monitoring

Employee
Return-to-Work
Programs



Screening for Symptoms of COVID-19 & Infectious Diseases

Infections including COVID-19, produce unique physiological patterns that our solution will detect, assess and determine the probability of that person being infected or not infected.

As the virus mutates, our AI will learn how new symptoms present new patterns from which to continue detecting infection.

PredictMedix is critical even after an effective, safe vaccine has successfully been deployed to at least 80% of the global population in the coming years as annual flu and other infectious diseases proliferate

1

Quick, non-invasive, contactless screening

2

Fully automated without the need for personnel to operate

3

Indicates positive or negative result so safety protocols can be initiated

Easy to deploy in any indoor and outdoor location

Workplaces, Retail, Institutions & Buildings

Pilots and partnerships with major companies already in progress including India Oil Corporation, ranked 117th in Fortune Global 500 list of world's largest companies with more than 33,000 employees and \$85 billion in revenue.



Screening for Cannabis & Alcohol Impairment

Employers, as well as law enforcement, test people for traces of cannabis, alcohol and opioids. However, they cannot determine if individuals are actually impaired.

Without the ability to determine impairment, it is not possible to accurately predict safety risk, particularly for cannabis which is now medically prescribed.

Rather than test for traces of substances, PredictMedix uses multispectral recognition technologies to capture data used by our AI models to screen for impairment due to these substances

1

Quick, non-invasive, contactless screening

2

Fully automated without the need for personnel to operate

3

Indicates positive or negative result so safety protocols can be initiated

First to market

PredictMedix first-to-market AI product screens for Cannabis impairment.

The PredictMedix AI model is being expanded to include screening for alcohol and opioids.

Tech Mahindra, a multi-billion dollar IT company with fortune 500 clients, has partnered with PredictMedix to pilot and rollout our technology.



Mental Illness Diagnostic Screening

Mental illness is difficult to detect at early stages. Primarily due to a lack of diagnostic tools other than standardized surveys and subjective assessment from trained healthcare practitioners.

PredictMedix will use multispectral image patterns to effectively determine signs of mental illnesses, including depression, dementia and Alzheimer's

PredictMedix deployed in healthcare facilities and medical offices will provide practitioners with a simple, measurable diagnostic tool to detect signs of these disorders at early stages.

1

Quick, non-invasive,
contactless
screening

2

Fully automated
without the need for
personnel to operate

3

Indicates positive or
negative result so safety
protocols can be initiated

First diagnostic tool

PredictMedix Mental Illness Diagnostic Screening is a disruptive AI technology that will be the first solution of its kind to give healthcare practitioners the opportunity to provide proper care before their patients' condition worsens.

Max Healthcare has partnered with PredictMedix to provide data for the development of AI diagnostic models for mental illness.



Mobile Wellbeing – Next Gen Virtual Care

Remote patient monitoring & telehealth platform for healthcare, LTC and employers

PredictMedix has acquired Mobile Wellbeing (MWB) to provide screening clients with an end-to-end solution, and to leverage a rapidly growing market for remote care in hospital settings as well as for specific high value sectors, including:

Long Term Care (LTC) and Retirement Residences

Covid-19 has revealed the devastating shortfalls in elder care that can be addressed by MWB's tools, giving families transparency of care being delivered to their loved ones

Clinical Research Organizations (CRO)

Traditional methods of on-site monitoring for clinical studies of medicines and vaccines has been greatly obstructed due to the current pandemic, and can be better managed using MWB to provide rigorously detailed virtual oversight and compliance

Large Scale Employees

Existing human resource platforms cannot provide managed return-to-work programs for employees diagnosed with Covid-19 or other infectious diseases, which can be best facilitated through MWB's integration with PredictMedix Screening Products or as a stand-alone tool



Mobile Wellbeing

Putting care into telehealth

PredictMedix has partnered with Versus Systems to integrate Versus' proprietary rewards platform



Wearables and Bluetooth

Makes it easy for patients to share their vitals through the platform, and to give healthcare practitioners accurate, instant data to provide highly responsive care



Reward Programs

Incentivises compliance to promote better outcomes and a more enjoyable care experience



Engagement tools

From video to multiple communication channels, patients and practitioners, employees and HR professionals, will have comfortable ways to stay in touch and manage progress through care programs



Science & Patents

Protecting IP for Future Growth

6 US PATENTS HAVE BEEN FILED

IMPAIRMENT (1)

INFECTIOUS DISEASE SYMPTOMS (1)

MOBILE WELL-BEING (4)

Fatigue has adverse effects in both physical and cognitive abilities. Thermal imaging and facial analysis provide a mean to detect changes in the human body unobtrusively and in variant conditions of pose and illumination. Studies have demonstrated automatic detection of exercise-induced fatigue using thermal cameras and facial images, by analyzing them using deep convolutional neural networks. Furthermore, results indicate that classification of fatigued individuals is possible, obtaining an accuracy that reaches over 80% when utilizing single thermal images.⁹

Similarly, thermal imaging has also been explored as a tool for identification of nasal congestion. Moreover, studies have reported thermography as a better tool than X-rays in diagnosing frontal and ethmoidal sinusitis and as good as X-ray PNS and nose in diagnosing maxillary sinusitis.² Ocular abnormalities consistent with keratoconjunctivitis³, commonly referred to as pink eye, as well as conjunctival hyperemia, chemosis, epiphora, or increased secretions⁴, have been shown to occur in patients with Covid-19.

Breathing function consists of inspiration and expiration cycles during which heat exchanges occur. Thermal cameras generate a periodic or quasiperiodic thermal signal in between high (expiration) and low (inspiration) values. This imaging system at a distance, achieving an accuracy of

is usually positioned near the nostrils to capture this breath signal. Thermal imaging behaves therefore as a non-invasive process, but at a distance. The estimation of breathing rate is as proved by comparison with respiratory ground-truth [47,48]. Murthy et al¹⁰ found a high degree of chance in breathing rate estimation from airflow monitored through thermal imaging and oro-nasal temperature between the thermal and mechanical recordings over the same

visible and thermal imaging to monitor the breathing rate. Thermal imaging of the nose and mouth detection through a cascade classifier tracking of these regions over time. ROIs coordinates were extracted from thermal video. In terms of breathing rate estimation, the proposed method and the Bland-Altman plot with 95% confidence interval [39].

In several studies to be a reliable way for estimating breathing rate, thermal imaging technology for screening symptoms associated with COVID-19.

Thermal imaging performance that includes both an increase in the breathing rate and an eventual inability to produce this force.

Thermal imaging in the Diagnosis of Chronic Sinusitis. Cureus. 2020;13(12):e2298. <https://doi.org/10.7755/cureus.2298>.
Findings of Patients With Coronavirus Disease 2019 (COVID-19) in the Emergency Department. *JAMA Ophthalmol*. 2020;138(12):1575-1578. doi:10.1001/jamaophthalmol.2020.1291.
breathing function. *IEEE Eng. Med. Biol. Mag.* 2006; 25, 57-67.
Thermal imaging of the face. *IEEE Eng. Med. Biol. Mag.* 2006; 25, 57-67.
Thermal imaging of the face. *IEEE Eng. Med. Biol. Mag.* 2006; 25, 57-67.
Thermal imaging of the face. *IEEE Eng. Med. Biol. Mag.* 2006; 25, 57-67.
Thermal imaging of the face. *IEEE Eng. Med. Biol. Mag.* 2006; 25, 57-67.

Page 2 of 3

Predictmedix Science Based Technology to Identify Persons Exhibiting Symptoms of Covid-19 and Other Infectious Diseases

July 6, 2020

Predictmedix is developing a proprietary Artificial Intelligence (AI) technology (patent pending) to identify persons who are presenting science-based symptomatic evidence of Covid-19, as well as other infectious diseases including Influenza.

The AI powered technology utilizes multispectral imaging cameras and ancillary sensors as data collection sources. These cameras and sensors provide the Predictmedix AI Covid-19 & Infectious Disease Screening Model with visual spectral imaging plus infrared thermography that falls outside of visual spectrum wavelengths. This data is processed using a Cloud/Edge configuration comparing, in real time, the complex thermographic patterns of persons being screening with learned data sets from healthy control groups and Covid-19 patients.

The result is an evidence-based determination that outputs a probability of infection or no infection. Built as an AI machine learning system, the Model continuously evolves as more data is received through screenings and from testing partners providing the most recent physiological patterns associated with symptoms of the virus. These include currently known symptoms of fatigue, headache, coughing, congestion, difficulty breathing and fever, which in turn have identifiable features based on blood flow, sweat gland activation, eye redness and other physiological processes.

As demonstrated by several studies, physiological patterns can be identified through multispectral cameras, and when used in proper combination can be used to assess the probability of an individual exhibiting symptoms associated with Covid-19 infection.

The utility of thermal imaging in identification of headaches has been explored in several studies over the past forty years. In 1997, Ford et. al. reviewed thermograms of 993 suitable patients with migraine with and without aura, chronic daily headache, cluster headache, posttraumatic headache, and a variety of other headache types.¹

Eight hundred fifty-five (86.1%) had abnormal thermograms usually characterized by decreased supraorbital thermal emission. Six hundred ninety-four (69.9%) of 993 had migraine without aura of whom 593 (85.4%) had abnormal thermograms. Two hundred two (20.3%) of 993 had migraine with aura, of whom 180 (89.1%) had abnormal thermograms. Thirty of 35 (85.7%) patients with cluster headache, and 28 of 33 (84.8%) with posttraumatic headache had abnormal thermograms. Twenty-four of 29 (82.8%) of patients with various less common headaches and head pain syndromes had abnormal thermography. The study concluded infrared thermography as being a useful diagnostic test in the management of headaches.

¹ Ford RG, Ford KT. Thermography in the diagnosis of headache. *Semin Neurol*. 1997;17(4):343-349. doi:10.1055/s-2008-1040947.

Page 1 of 3

to not determine symptomatic evidence of Covid-19

of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

cold or hot weather will produce different skin temperature. If the person has been inside acclimatizing to the room wears a heavy coat, for example, their sweat glands will be active. When removing their coat, the skin temperature for a period of time which is slightly different for each

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

the absence of additional science-based symptomatic evidence of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.



Partnerships

The biggest and best believe in our solutions



Tech Mahindra

PREDICTMEDIX has signed Joint Venture agreements with Tech Mahindra for PREDICTMEDIX screening technology.

Tech Mahindra will resell PREDICTMEDIX to their global client base, having already participated in a successful pilot test with our team.

Top 15

GLOBAL IT COMPANIES BY FORBES

\$4.9B

COMPANY OWNED BY MAHINDRA GROUP, A \$420.7BN FEDERATION OF COMPANIES



Max Healthcare

Max Healthcare will provide testing and data for PREDICTMEDIX to use in the continued development of our AI screening models.

One of India's leading providers of comprehensive healthcare services with a network of:

14

HOSPITALS

2,300+

LEADING DOCTORS



Indian Institute of Technology (IIT)

Indian Institute of Technology (IIT), renowned for training the world's top technology engineers, provides us with talented engineers and AI specialists who work with our senior team to develop platform functionality and enhance machine learning for our AI models.

Top Ranked

ENGINEERING SCHOOL GLOBALLY

Alumni:

CEO's & CTO's

WORKING AT MANY FORTUNE 500 COMPANIES INCLUDING GOOGLE, IBM AND MICROSOFT



Business Model & Current Activity

Clients pay a monthly fee based on tiered volume of screenings providing PredictMedix with recurring monthly revenue and multi-year contracts through a network of resellers.

We are in process of deploying Covid-19 & Infectious Disease Symptom Screening Units at client sites through our resellers in US, Canada, India and UK

We currently have signed agreements with three companies to DISTRIBUTE and RESELL our solutions

North America

**Juiceworks
Exhibits**

UK

**Taurus
Medical**

India

**Tech
Mahindra**

Other regions will be developed through similar agreements

flow

Flow Water, one of the fastest growing premium water brands in North America, uses PredictMedix Covid-19 & Infectious Disease Symptom Screening to keep their workplace safe





Mainstream, trade and investor media

are actively pursuing PredictMedix for interviews and features.

PredictMedix Inc. Announces Filing of Two US Patents and a Sales Contract for the United Kingdom



INVESTORINTEL | JULY 07, 2020 | NO COMMENTS



Special Edition 13: Predictmedix brings AI to Canadian Retail including COVID-19 Screening

May 26, 2020

An off-schedule podcast discussion with Dr. Rahul Kashwah, the co-founder and Chief Operating Officer at PredictMedix Inc., an artificial intelligence (AI) company with technology that tests for symptoms of COVID-19 and can be used to monitor spaces. Dr. Kashwah discusses how PredictMedix AI can screen for COVID-19 and physical distance enforcement in stores, malls, and any physical space.



Predictmedix Announces Acquisition of Telemedicine Platform – MobileWellbeing

Predictmedix Inc. and Juiceworks Provide Safe Entry Solutions to Facility Managers at IFMA World Workplace in Texas

PUBLISHED
SEP 3, 2020 8:00AM EDT

by @accesswire on 26 Jun 2020, 08:01

Predictmedix and Tech Mahindra to Offer AI Based Healthcare Solution for Post COVID-19 Environment



Recent Developments

Past 6 Months



Patents

- 5 US patents filed
- Filing of 1 US patent for symptom screening technology
- Filing of 4 US patents for our remote patient monitoring platform



Key Appointments and Partnerships

- Appointment of Mr. Kapil Raval to chair our advisory board and assist with business development
- Appointment of Mr. Prabhakar Srivastava to play a key role in business development in Africa and Asia-Pacific
- Appointment of Kiran Kumari, senior oil and gas executive who has assisted large multinationals with business development in Asia
- Alliance with Max Healthcare along with appointment of Dr. Banerji to assist us with technology development
- Appointment of renowned clinicians to assist us with technology development



Business Development

- Execution of sales contract with Juiceworks Exhibits for US and Canada
- Execution of sales contract with Taurus medical in the UK
- Collaboration with Tech Mahindra, the highest ranked Non-U.S. company in the Forbes Global Digital 100 list (2018) and in the Forbes Fab 50 companies in Asia (2018).



Deployments

- Successful deployment at Flow Water, fast growing brand available at over 20,000 retailers across the United States, Canada and Europe.
- Deployment at logistics stage for Indian Oil Corporation Ltd., India's largest downstream oil company, with a workforce of more than 33,000 employees and 2019 revenue of US\$85 billion.
- Planned deployment at International Facility Management Association (IFMA) conference
- Several other deployments in planning stages to be announced



Acquisitions


- Acquisition of Telemedicine/Telehealth/Remote patient monitoring platform Mobile WellBeing
- Mobile WellBeing has been successfully trialled at several hospitals in North America



Covid-19 & Infectious Disease Symptom Screening

Competitive Landscape

Company	AI	Non-Invasive	Temperature Detection	Multi-Symptom Detection	Notes	Commercialization Stage
	✗	✓	✓	✗	Potentially introducing more symptom detection	Launching
	✗	✓	✓	✗	Indicates it is AI Enabled which may mean future versions will use AI in some fashion	Launching
	✗	✓	✗	✗	Tests air which means exposure potential already high	Pre-commercialization
 PREDICT MEDIX	✓	✓	✓	✓	AI powered symptom detection screening	Pilots Launched



PREDICT MEDIX


Focuses its development on disruptive technologies powered by machine learning AI to keep people safe whether they gather for work or play, without the need for invasive testing or long waiting times to get results



Cannabis & Alcohol Impairment Screening

Competitive Landscape

Company	AI	Non-Invasive	Impairment Detection	Notes	Commercialization Stage
 CANNABIX TECHNOLOGIES INC.	✗	✗	✗	Breathalyzer	Pre-commercialization
 HOUND LABS™	✓	✗	✓	Unknown how it determines impairment and may rely on amount of cannabinoids to apply a rating for potential impairment similar to alcohol breathalyzer tests	Pre-commercialization
 PREDICT MEDIX	✓	✓	✓	Non-invasive screening that uses machine learning AI models to assess impairment unique to each individual	Product Development



P R E D I C T M E D I X

Focuses its development on disruptive technologies powered by machine learning AI to keep people safe whether they gather for work or play, without the need for invasive testing or long waiting times to get results



Leadership Team



Sheldon Kales
CEO

- Expertise in operations, business strategy and capital markets
- Held leadership roles operating R&D companies in the USA, Canada and the Middle East
- Led companies from start-up stages through growth and successful exits



Dr. Rahul Kushwah
COO

- PhD, Banting Fellow (one of 23 global recipients in medicine)
- Developed world's first genetic test for cannabis pharmacogenetics
- Previously on the National Research Council for the Government of Canada in Human Health Therapeutics
- Expertise in human diseases, genetics, immunology and regenerative / personalized medicine



Rakesh Malhotra
CFO

- CPA designation in US and Canada, FCA
- Over 25 years in accounting, financing and internal controls
- Has held senior management positions in publicly traded companies



Nandan Mishra
Co-AI Lead

- Artificial Intelligence pioneer in translational research for AI
- Masters in Systems Biology and Bachelors Degree in Engineering from the Indian Institute of Technology
- Member of the prestigious National Mission of Interdisciplinary Cyber Physical Systems of India (a federal technology think tank)



Himanshu Ujjawal Singh
Co-AI Lead

- Specialization in Data Analytics and AI
- Consulted with several multinational corporations in setting up their analytics practice in the field of telecom, healthcare, retail and workforce analytics
- Expertise in data monetization



Praveen Kumar
Data Analytics Lead

- Specialization in Data Analytics, Machine Learning and Deep Neural Networks
- Worked with several top Fortune 500 companies
- Consulted with top financial corporations in Canada



Rajiv Muradia
MWB Product Lead

- Mobile Wellbeing Founder
- Executive entrepreneur with experience in technology, management and business development
- Rajiv has successfully founded several companies and has helped a number of start-ups with their product strategy, positioning and technology visions



Board of Directors



Sheldon Kales

- Expertise in operations, business strategy and capital markets
- Held leadership roles operating R&D companies in the USA, Canada and the Middle East
- Led companies from start-up stages through growth and successful exits



Dr. Rahul Kushwah

- PhD, Banting Fellow
- Developed world's first genetic test for cannabis pharmacogenetics
- Previously on the National Research Council for the Government of Canada in Human Health Therapeutics
- Expertise in human diseases, genetics, immunology and regenerative / personalized medicine



Ajit Kumar

- Seasoned healthcare business leader
- Founder of K-Med Ltd.; among the largest suppliers of healthcare and medical equipment in the UK with operations in the Middle East, EU and Africa



Tomas Sipos

- Seasoned investment banker
- Has held several senior positions, including VP, Mergers and Acquisitions of Ernst & Young, Managing Director of Investment Banking at European Privatization & Investment Corporation and Senior Investment Banker for the International Finance Corporation
- Presently, CFO for Pistil Partners Inc., and serves as a director of NATO Association of Canada Program Committee



Advisory Board

Kapil Raval

Advisory Board Chair
Director of AI, Business Development, Microsoft

Global Business Leader with 25+ years experience. Kapil is currently a director at Microsoft, driving business development for AI solutions for different industries globally.

Having worked for global organizations like Philips, DEC, Compaq and HPE and Microsoft in Americas, Middle East and APJ, Kapil brings understanding of global cultural and market nuances, inventiveness and problem-solving skills.

Prabhakar Srivastava

Business Development

Senior Healthcare Executive with over 38+ years experience including CEO of an Indo-Israeli Venture. Mr. Srivastava has been pivotal in launching state-of-the-art innovative solutions for indigenous production through Transfer of Technology in healthcare & environment fields from companies including Phillips Medical Systems, Picker International Inc, Elscint Ltd., Medison Co. Ltd. and Toshiba Corporation.

Additionally, he has served as advisor to several African Countries viz. Uganda, Republic of Burundi & Federal Republic of Nigeria along with the government of India.

Dr. Deepu Banerji MSc, PhD

- Neurosurgeon with over 34 years' experience in microscopic and minimal invasive neurosurgery
- Sugita Fellow from Nagoya University, Japan for micro neuro-surgical training
- Consistently ranked amongst the top 5 neurosurgeons in India.

Dr. Indranil Saha PhD

- Assistant Professor, Computer Science & Engineering, IIT
- Expert in the areas of Artificial Intelligence and Robotics
- Received the ACM SIGBED Frank Anger Memorial Award in 2012 for his contribution in the intersection of embedded systems and software engineering

Dr. Nitin Kadam MBBS, DHC, MD

- Professor at M.G.M. Medical College Mumbai
- Management team member for M.G.M. group of colleges and hospitals
- Director of M.G.M.'s New Bombay Hospital
- Management Council Member, M.G.M. University of Health Sciences, Academic Council & Board of Studies

Dr. Dawn Decunha

- Clinical Psychologist and educator
- Specialty in emotional trauma, psychiatric and psychological trauma

Kiran Kkumari

- Senior oil and gas executive who has assisted some of the largest multinational conglomerates with business development in Asia.

Dr. Navdeep Singh Nanda MBBS, MS, DNB

- One of India's leading thoracic surgeons, practicing in BLK Super Speciality Hospital, the largest stand-alone private sector hospital in India
- Immense experience in the field of thoracic surgery, thoracic oncology, VATS, robotic chest surgery and related research

Dr. Mike Hart MD

- Early adopter of medicinal marijuana applications in medical practice, opening first of its kind facility in London, Ontario
- "Expert" guest on the subject of medicinal marijuana, appearing on CTV news, Rogers TV, CBC National Radio, Toronto Star and Canadian Consortium for the Investigation of Cannabinoids

Dr. Alexander D. Bardon CCFP(EM)

- Emergency Room physician for over 6 years
- Expertise in infectious disease and screening
- Works in 3 different hospital emergency departments: Norfolk General, St. Mary's General and Grand River Hospital
- Associate Clinical Professor at McMaster University

Dr. Tally Bodenstein PhD

- Practicing psychologist for over 20 years
- Speciality in children, adolescents and families



Capital Structure

Authorized Capital
Unlimited

Fully Diluted Shares
111,902,149

Shares Issued & Outstanding

100,054,149*

Most Recent Financing

3,296,000 @ \$0.25

Warrants

1,648,000 @ \$0.50

EXPIRY: AUGUST 2021

Incentive Stock Options

9,850,000 @ \$0.15

EXPIRY: APRIL 6, 2021

350,000 @ \$0.10



Future Outlook

The Board of Directors and management team believe the growing need for rapid, mass, early stage screening is critical for governments, healthcare and employers.

We also see that the heightened environment of anxiety caused by the COVID-19 pandemic is accelerating adoption of these technologies.

Particularly for disruptive AI powered technologies such as PREDICTMEDIX that eliminate the need for biologics and can be deployed virtually anywhere without the need for onsite personnel to operate the solutions.



COVID-19 & Infectious Disease Symptom Screening

- Pilots and rollouts in US, Canada, UK, India and other regions currently in discussion phases
- Completion of clinical studies with Max Healthcare and potentially two other healthcare and university institutions in Canada and India
- Enhancement of AI models using clinical data to further advance multi-symptom detection



Drug & Alcohol Impairment Screening

- Completion of study with over 3,000 participants
- Refinement of AI models to improve impairment detection
- Pilot programs with partners and new companies to be followed by extensive rollouts



Mental Illness Diagnostic Screening


- US patent filings
- Development of AI models based on data provided by clinical partners
- Launch of pilots in healthcare settings



Mobile Wellbeing Remote Care Platform

- Completion of upgraded development and sector specific features
- Launch of platform versions for targeted sectors
- Pilot and rollout programs





P R E D I C T M E D I X

PREDICTMEDIX.COM



CORPORATE INFORMATION

77 King Street West, Suite 3000
Toronto, ON, Canada M5K 2A1

INVESTOR RELATIONS

Ehsan Agahi
IR@predictmedix.com

